<figure><img src="image_1.png" /></figure>

HAL
open science

# Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy

Mengwu Pan, Valeria Solozobova, Nane Kuznik, Nicole Jung, Simone Gräßle, Victor Gourain, Yvonne Heneka, Christina Cramer von Clausbruch, Olaf Fuhr, Ravi Munuganti, et al.

► To cite this version:

Mengwu Pan, Valeria Solozobova, Nane Kuznik, Nicole Jung, Simone Gräßle, et al. Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer Research Communications, 2023, 3 (7), pp.1378-1396. 10.1158/2767-9764.CRC-23-0111. inserm-04215247

HAL Id: inserm-04215247

https://inserm.hal.science/inserm-04215247

Submitted on 22 Sep 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
# Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy

<figure><img src="image_2.png" /></figure>

Mengwu Pan<fnref n="1" />, Valeria Solozobova<fnref n="1" />, Nane C. Kuznik<fnref n="1" />, Nicole Jung², Simone Gräßle², Victor Gourain³, Yvonne M. Heneka², Christina A. Cramer von Clausbruch<fnref n="1" />, Olaf Fuhr⁴, Ravi S. N. Munuganti⁵, Danilo Maddalo<fnref n="1" />, Christine Blattner<fnref n="1" />, Antje Neeb<fnref n="6" />, Adam Sharp<fnref n="6" />,⁷, Laura Cato⁸,<fnref n="9" />, Carsten Weiss<fnref n="1" />, Rinath M. Jeselsohn⁸,<fnref n="9" />, Veronique Orian-Rousseau², Stefan Bräse²,¹⁰, and Andrew C. B. Cato<fnref n="1" />

## ABSTRACT

The pro-oncogenic activities of estrogen receptor alpha (ERα) drive breast cancer pathogenesis. Endocrine therapies that impair the production of estrogen or the action of the ERα are therefore used to prevent primary disease metastasis. Although recent successes with ERα degraders have been reported, there is still the need to develop further ERα antagonists with additional properties for breast cancer therapy. We have previously described a benzothiazole compound A4B17 that inhibits the proliferation of androgen receptor-positive prostate cancer cells by disrupting the interaction of the cochaperone BAG1 with the AR. A4B17 was also found to inhibit the proliferation of estrogen receptor-positive (ER+) breast cancer cells. Using a scaffold hopping approach, we report here a group of small molecules with imidazopyridine scaffolds that are more potent and efficacious than A4B17. The prototype molecule X15695 efficiently degraded ERα and attenuated estrogen-mediated target gene expression as well as transactivation

by the AR. X15695 also disrupted key cellular protein-protein interactions such as BAG1-mortalin (GRP75) interaction as well as wild-type p53-mortalin or mutant p53-BAG2 interactions. These activities together reactivated p53 and resulted in cell-cycle block and the induction of apoptosis. When administered orally to *in vivo* tumor xenograft models, X15695 potently inhibited the growth of breast tumor cells but less efficiently the growth of prostate tumor cells. We therefore identify X15695 as an oral selective ER degrader and propose further development of this compound for therapy of ER+ breast cancers.

**Significance:** An imidazopyridine that selectively degrades ERα and is orally bioavailable has been identified for the development of ER+ breast cancer therapeutics. This compound also activates wild-type p53 and disrupts the gain-of-function tumorigenic activity of mutant p53, resulting in cell-cycle arrest and the induction of apoptosis.

## Introduction

Breast cancer is the most commonly diagnosed cancer worldwide with over 2.3 million new cases and 685,000 deaths in 2020. In 2040, the burden of breast cancer is predicted to increase to over 3 million new cases and 1 million deaths every year because of population growth and ageing (1). Approximately

70%-80% of breast cancers are dependent on estrogen receptor (ER) signaling for oncogenic growth and progression (2). Therapies that block the synthesis of estrogens or directly target the ER are highly effective for treating ER-positive (ER+) breast cancers. However, acquired resistance to the ER-directed therapies arises that reduce the efficacy of the drugs leading to poor clinical outcomes. The endocrine therapies normally used are compounds that inhibit estrogen

Massachusetts. ¹⁰Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany.

M. Pan and V. Solozobova contributed equally to this article.

**Corresponding Author:** Andrew C. B. Cato, Institute of Biological and Chemical Systems - Biological Information Processing, Karlsruhe Institute of Technology, Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen 76344, Germany. Phone: 00497-21608-22146; Fax: 00497-21608-23354; E-mail: andrew.cato@kit.edu

doi: 10.1158/2767-9764.CRC-23-0111

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

© 2023 The Authors; Published by the American Association for Cancer Research

<footnote n="1">¹Institute of Biological and Chemical Systems - Biological Information Processing, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany. ²Institute of Biological and Chemical Systems - Functional Molecular Systems, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany. ³Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France. ⁴Institute of Nanotechnology and Karlsruhe Nano Micro Facility (KNMFI), Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany. ⁵Vancouver Prostate Centre, Vancouver, British Columbia, Canada.</footnote>

<footnote n="6">⁶Institute of Cancer Research, London, United Kingdom. ⁷The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. ⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.</footnote>

<footnote n="9">⁹Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston,</footnote>
biosynthesis (e.g., aromatase inhibitors) or compounds that competitively mod-
ulate the action of ERα (e.g., selective ER modulators—SERM). Long-term
treatment with the SERM tamoxifen is reported to promote endometrial carci-
noma and venous thromboembolism due to partial ERα agonistic activity (3).
Second- and third-generation SERMs have therefore been developed that show
improved, though distinctly different, safety profiles compared with tamoxifen.
However, the risk of venous thromboembolism remains a concern for most
SERMs (4). In contrast, selective estrogen receptor degraders (SERD) are con-
sidered pure antagonists without agonist activity. They do not only antagonize
ERα action but also downregulate ERα protein levels. One of the earliest ex-
amples of such a targeted protein degradation therapeutic is fulvestrant, that
shows efficacy in tamoxifen-refractory patients and postmenopausal women
who had progressed on prior hormone therapies (5) However, fulvestrant's ma-
jor clinical limitations are its intramuscular route of administration and its low
bioavailability (6–8). There is therefore the need for the development of orally
bioavailable ER degraders (9). A number of such oral SERDs have been de-
scribed that exhibit both preclinical and clinical antitumor activities (10, 11) but
despite these promising results, there is still an opportunity to develop further
ERα antagonists with novel modes of action.

We aim to develop novel ERα inhibitors that do not competitively interact with the ligand-binding domain of the receptors where mutations mostly occur that block the action of the antagonists. Rather, we have embarked on the development of new antagonists that target molecular chaperones and cochaperones that assist the conformational folding or unfolding as well as the assembly of other macromolecular structures including steroid receptors. One such attractive group of proteins to target is the BCL2-associated athanogene protein 1 (BAG1), a nucleotide exchange factor that binds the ATPase binding domain of the molecular chaperone HSP70/HSC70. In addition to its co-chaperone activity, BAG1 interacts with a variety of other proteins to regulate diverse cellular processes including cell division, cell death and differentiation, and transcriptional activity of the ER and androgen receptor (AR).

BAG1 is made up of different proteins translated from a single mRNA by al-
ternative translation-initiation resulting in humans in four BAG1 isoforms (IL,
1M, 1, and 1S). These proteins have a similar carboxy-terminal BAG domain
that is made up of three antiparallel alpha helical bundles of 30–40 amino acids
(12) and a centrally located ubiquitin-like domain that directs HSP70 clients to
the proteasome for degradation (13, 14). The largest member of the family pos-
sesses a N-terminal nuclear localization sequence and is therefore localized to
the nucleus where it interacts with and regulates the activity of transcription
factors including ERα and the AR (15–17). The other BAG1 proteins are cyto-
plasmic and they regulate an array of molecular targets within the cytoplasm
that control cell proliferation, apoptosis, and stress response (18).

We have recently described a benzothiazole-based compound A4B17 with an-
tiproliferative action in ER⁺ breast and AR-positive (AR⁺) prostate cancer cells
that is reported to dock into the BAG domain of BAG1 (19, 20). This compound
attenuated AR target gene expression by disrupting the interaction of BAG1 and
the AR N-terminal domain that is otherwise required for transactivation by
the AR. However, it required micromolar concentrations for its action. To im-
prove on the efficacy of A4B17, we used scaffold hopping strategies to change
the chemical scaffold of A4B17 and analyzed the resulting compounds for their
antiproliferative action in breast and prostate cancer cells. We identified an im-
idazopyridine X15695 that potently inhibited proliferation of ER⁺ breast and
AR⁺ prostate cancer cells. X15696 degraded ERα protein and potently inhibited

ERα transactivation and in addition reactivated p53 by disrupting its interac-
tions with members of the HSP70 chaperone family. In mouse tumor xenograft
models, when administered orally, X15695 inhibited ER⁺ breast cancer cell
growth more efficiently than prostate cancer cell growth. These studies together
identify X15695 as an oral SERD for further development for the treatment of
breast cancer.

**Materials and Methods**

Drugs and Chemicals

17-β-estradiol (Sigma-Aldrich, E8875; PubChem SID 24278426), fulvestrant (Sigma-Aldrich, I4409; PubChem SID 329815373), tamoxifen (Sigma-Aldrich, T5648), 5α-Androstan-17β-ol-3-α [Dihydrotestosterone (DHT); Merck A8380], Enzalutamide (MDV3100; Selleckchem S1250), H2DCF-DA (Thermo Fisher Scientific, D399), 4',6-Diamidino-2-phenyllindole dihydrochloride (DAPI; Sigma-Aldrich, D9542), DRAQ5 (BioStatus Limited, DR50050), cycloheximide (Sigma-Aldrich 239763), MG132 (Calbiochem 4745790), 7-Aminoactinomycin D (7-AAD; Thermo Fisher Scientific A1310), etoposide (Sigma-Aldrich, E1383; PubChem SID 24278178), NAC (N-acetyl-L-cycteine; Santa Cruz Biotechnology, sc-202232), Hoechst stain 33,258 (Abcam, ab228550), Hoechst stain 33,342 (Invitrogen, 62249), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, 1.11714), 2'-7-dichlorofluorescein diacetate (H2DCF-DA; Thermo Fisher Scientific D399), Lipofectamine 2000 (Thermo Fisher Scientific 11668027), Protein A-agarose beads (Thermo Fisher Scientific, 20333), Protein G-agarose beads (Thermo Fisher Scientific 11668027), Mowiol 4-88 (Sigma-Aldrich, 81381).

Cell Lines

All cell lines were obtained from the ATCC: MCF-7 (RRID:CVCL_0031), ZR-75-1 (RRID:CVCL_0588), MDA-MB-231 (RRID:CVCL_0062), LNCaP (CRL-1740, RRID:CVCL_0395), LAPC-4 (CRL-13009, RRID:CVCL_4744), PC3 (CL-1435, RRID:CVCL_0035), 22Rv.1 (CRL-2505, RRID:CVCL_1045), DU145 (CRL-HTB-81, RRID:CVCL_0105), HeLa (CCL-2, RRID:CVCL_0030), A549 (RRID:CVCL_0023), U2OS (RRID:CVCL_B0A7). Cells were all *Mycoplasma*-free upon receipt from ATCC prior to 2015. The identities of the cells were confirmed by short tandem repeat profiling (BioSynthesis and DSMZ). Cells were typically grown up to 20–30 passages. BAG1 short hairpin RNA (shRNA) knockdown and shRNA control LNCaP (shRNA control, 506-2, 606-2) were generated by transducing LNCaP cells transduced with predesigned BAG1 MISSION shRNA lentiviral transduction particles in pLKO.1; clones NM_004323.2-506s1c1 (clone 506) and NM_004323.2-666s1c1 (clone 666) or pLKO.1 non-silencing control (clone control C2), respectively (Mission; Sigma-Aldrich). TRMCF-7 cells are described in Morrison and colleagues, 2014 (21). All cell lines are routinely confirmed to be *Mycoplasma*-free, using the VenorGeM Classic Mycoplasma Detection Kit for conventional PCR (Minerva Biolabs, 11-1250). MCF-7, TRMCF-7, T47D, ZR-75-1, MDA-MB231, LNCaP, shRNA control and BAG1 shRNA knockout LNCaP, 22Rv.1, PC3, DU145, and LAPC-4 cells were cultured in RPMI1640 supplemented with 10% FBS, 1% penicillin/streptomycin at 37°C in an incubator with 5% CO₂ and 90% humidity. LAPC-4 cells were additionally supplemented with 1 nmol/L DHT. HeLa, A549, and U2OS cells were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 U/mL). For experiments requiring hormone starvation, cells were cultured for 72 hours in phenol red-free RPMI1640 medium, supplemented with 3% charcoal-stripped FCS.
## p53 siRNA Knockdown and Western Blotting

Transfection experiments with siRNA were performed using Lipofectamine 2000 according to the manufacturer's instructions using SMARTpool ON-TARGETplus siRNA against p53 (Horizon Discovery, L-003329-00-0005). Briefly, $5 \times 10^4$ cells were transfected with 6 µL of Lipofectamine 2000 and 10 nmol/L p53 siRNA or control siRNA (5'-GGUGCGCUCCUGGACGUA GCC-3'; Eurofins Genomic). Sixteen hours after transfection, the medium was changed and X15695 or vehicle was added to the cells for 72 hours for proliferation assay or 24 hours for protein analysis. For Western blotting, cells were lysed in NP-40 lysis buffer (1% NP-40, 50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 5 mmol/L Ethylenediaminetetraacetic acid [EDTA]) or 1x passive lysis buffer (Promega, E1941) for 15 minutes on ice. Cell debris was removed by centrifugation at 13,000 rpm for 10 minutes and cleared lysates used for SDS-PAGE and Western blotting.

Western blotting was carried out using standard protocols with antibodies: p53 (Thermo Fisher Scientific, catalog no. MA5-14516, RRID:AB_11008717), Mdm2 (Abcam catalog no. ab-260074 RRID:AB_2936956), p53 (clone DO-1; Santa Cruz Biotechnology catalog no. sc-126, RRID:AB_628082), p53 Sp5 (Thermo Fisher Scientific, catalog no. MA1-39547, RRID:AB_2537220), BAG1 (Santa Cruz Biotechnology, catalog no. sc-33704, RRID:AB_626720), β-actin (Santa Cruz Biotechnology, catalog no. sc-47778, RRID:AB_626632), vinculin (Santa Cruz Biotechnology, catalog no. sc-25336, RRID:AB_628438), GAPDH (Santa Cruz Biotechnology, catalog no. sc-365062, RRID:AB_10847862), α-Tubulin (Santa Cruz Biotechnology, catalog no. sc-5286, RRID:AB_628411), ERα (Santa Cruz Biotechnology, catalog no. sc-8002, RRID:AB_627558), GRP75/Mortalin (Santa Cruz Biotechnology, catalog no. sc-133137, RRID:AB_2120468), AR (Santa Cruz Biotechnology, catalog no. sc-7305, RRID:AB_626671), BAG2 (Santa Cruz Biotechnology, catalog no. sc-390107 RRID:AB_2936954), and BAG5 (Santa Cruz Biotechnology, catalog no. sc-390832 RRID:AB_2936955), Goat anti-mouse Immunoglobulins/HRP (DAKO, catalog no. P0447, RRID:AB_2617137), Goat anti-rabbit Immunoglobulins/HRP (DAKO, catalog no. P0448, RRID:AB_2617138), Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Thermo Fisher Scientific, catalog no. A-11001, RRID AB_2534069), Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 (Thermo Fisher Scientific, catalog no. A-11035, RRID AB_2534093).

## Cycloheximide Chase and MG132 Stability Assay

Unless otherwise stated, cycloheximide chase and MG132 stability experiments were performed as follows: $2 \times 10^5$ MCF-7 cells were seeded in 6 cm dishes and treated with 1 µmol/L X15695 or the equivalent volume of DMSO for 24 hours. Thereafter, cells were incubated with the protein synthesis inhibitor cycloheximide (100 µg/mL) and harvested at timepoints 0, 30, 60, 90, and 120 minutes. Cells were lysed and used for Western blotting to determine the ERα level at each timepoint. For MG132 experiments, MCF-7 cells were similarly treated but in the presence or absence of the proteasome inhibitor MG132 (0.5 µmol/L) for 48 hours. Cells were harvested and lysed for Western blot assay to detect the p53 level at each condition.

## Co-immunoprecipitation

For co-immunoprecipitation experiments, $1 \times 10^6$ cells were seeded in 15 cm dishes and treated with 1 µmol/L X15695 or the equivalent volume of DMSO for 48 hours. Cells were harvested, washed with PBS and lysed using NP-40 lysis buffer. Protein A agarose beads were mixed with protein G agarose beads (4:1) and preincubated overnight at 4°C with anti-p53 or anti-BAG1 or con-

trol IgG antibody. Cellular extracts from X15695 treated and untreated cells (1,000 µg) were incubated with antibody-preincubated protein A/G agarose beads for 3 to 4 hours at room temperature. The beads with immunoprecipitated proteins were collected at 4°C by centrifugation at $1,000 \times g$ for 5 minutes and washed four to five times with NP-40 lysis buffer. The immunoprecipitated proteins were eluted by heating in SDS sample buffer for 5 minutes at 95°C and resolved on SDS-PAGE. Thereafter, they were subjected to Western blot analysis to detect mortalin, BAG1, BAG2, BAG5, and p53. Cellular extracts containing 50 to 70 µg protein from X15695 treated and untreated cells were used as the input control for the targeted proteins.

## RNA-sequencing and Quantitative RT-PCR Experiments

MCF-7, T47D, and LNCaP cells ($5 \times 10^4$ each) were seeded in 6-well plates and cultured with hormone-depleted medium for 3 days. Subsequently, the MCF-7 and T47D cells were treated with 10 nmol/L 17-β-estradiol ($E_2$) or DHT for the LNCaP cells, 1 µmol/L X15695 (for the MCF-7 and T47D cells) or 5 µmol/L for LNCaP cells and X15695 together with $E_2$ or DHT. A total of 1 hour pretreatment with X15695 was performed prior to treatment with $E_2$ or DHT for 16 hours. RNA was extracted using innuPREP RNA mini Kit 2.0 (Analytic Jena, 845-KS-2040250). A total of 1 µg RNA per sample was used as input material for the RNA sample preparations. Sequencing libraries were generated using NEBNext UltraTM RNA Library Prep Kit for Illumina (New England Biolabs, E7530L) following the manufacturer's recommendations and index codes were added to attribute sequences to each sample. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using PE Cluster Kit cBot-HS (Illumina) according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina platform and paired-end reads were generated. Library preparation and sequencing were carried out by Novogene Europe. The RNA-sequencing (RNA-seq) data were analyzed by R (v4.1.1, RRID:SCR_001905). Differential expression analysis was performed using R package Limma (v3.52.2, RRID:SCR_010943) and visualized with R package ggplot2 (v3.4.2, RRID:SCR_014601) with absolute values of log<sub>2</sub> fold changes ≥1 and p(FDR) ≤0.05. Gene Ontology analysis and gene set enrichment analysis (GSEA; RRID:SCR_006484) was performed using R package GSEABase (v1.58.0) and GSVA (v1.44.2) and the results were visualized by R package enrichplot (v1.16.1; refs. 22, 23). The data were deposited at the Gene Expression Omnibus repository under accession number GSE218556. Select target genes were analyzed by RT-PCR experiments with RNA from the samples used for the RNA-seq analysis. PCR analysis was carried out using the SYBR Green GoTaq PCR mix (Promega, A6002) and Rib36B4 as a housekeeping gene. The sequence of the primers used is in the Supplementary Data.

### MTT Cell Viability Assay

Cells were seeded in duplicates at a density of $1 \times 10^4$ cells/well in a 24-well plate format and incubated for 6 days in culture medium. Cells transfected with siRNA were incubated for 72 hours after X15695 addition. Thereafter, the medium was exchanged for a fresh medium containing 0.5 mg/mL MTT and incubated at 37°C for 2 hours until intracellular purple formazan crystals were formed. The MTT solution was removed and the purple crystals were dissolved in isopropanol and the optical absorbance at 590 nm was recorded using SpectraMax iD3, Molecular Devices.

### Clonogenic Assay

Cells were seeded at a density of $1–2 \times 10^3$ cells/well in a 6-well plate and treated with increasing concentrations of X15695 and cultured for 14–21 days. Medium and compounds were exchanged after 7 days. Cells were fixed with
methanol/acetic acid mixture [3:1 volume for volume (v/v)] and the formation of colonies was visualized using 0.5% crystal violet (w/v) in 20% methanol (v/v). Plates were scanned in a conventional office scanner (Epson). The area covered by colonies was calculated using the ColonyArea Plugin for ImageJ (RRID:SCR_003070; ref. 24).

## Reduced H2DCF-DA Oxidation Assay

MCF-7 and T47D cells were seeded at $1 \times 10^3$ cells and treated with $10^{-9}$ to $10^{-6}$ mol/L X15695 for 48 hours. Afterward, cells were loaded with 10 µmol/L H2DCF-DA in phenol red-free medium for 40 minutes. Cells were subsequently washed with medium and further incubated in medium for 120 minutes before analysis of fluorescence at 485 nm excitation and 530 nm emission using a multi-well fluorescence reader (SpectraMax iD3, Molecular Devices with SoftMax Pro 7 software). After the DCF assay, cells were frozen at -80°C overnight. After thawing, DNA was stained with a Hoechst dye 33258 (10 µg/mL final concentration) for 30 minutes at room temperature and fluorescence was measured at 352 nm excitation and 454 nm emission in a multi-well fluorescence reader (SpectraMax iD3, Molecular Devices with SoftMax Pro 7 software). DCF fluorescent intensities were normalized to Hoechst fluorescent intensities.

## Immunofluorescence Assay

For immunofluorescence assay, MCF-7, T47D, 22Rv1, LAPC-4, and LNCaP cells ($1 \times 10^4$ each) were seeded on coverslips in a 24-well plate and the desired treatment applied. After three times washing with PBS, cells were fixed with 4% paraformaldehyde solution for 10 minutes at room temperature. Next, the cells were washed three times with PBS and permeabilized with 0.5% Triton X-100 for 10 minutes at room temperature. Following three additional wash steps with PBS, cells were treated with 5% BSA (w/v) for 1 hour at room temperature and subjected to overnight incubation with the primary antibody p53 (DO1 clone or Sp5), ERα or mortalin/GRP75 and then washed three times with PBS followed by the incubation with goat anti-mouse IgG, Alexa Fluor 488 antibody and/or goat anti-rabbit IgG, Alexa Fluor 546 antibody for 1 hour at room temperature in the dark. All subsequent steps were performed in the dark. Cells were washed three times with PBS and stained with 0.1 µg/mL DAPI solution at 1:10,000 (v/v) dilution for 15 minutes at room temperature. After three times washing with PBS, the cells were mounted in Mowiol 4-88 on microscope slides and observed by laser-scanning confocal microscopy (Confocal Microscope platform STELLARIS6-LSM900, Leica).

## Flow Cytometry Assay

LNCaP, LAPC-4, MCF-7, and T47D cells were treated with 1 µmol/L X15695 or DMSO for 48 hours. Single-cell suspensions ($1 \times 10^6$ cells) were prepared in 150 µL PBS/10% FBS. Cells were fixed by addition of 5 mL ice-cold ethanol (70%) and incubated overnight at 4°C. Fixed LNCaP and LAPC-4 cells were stained with 20 µmol/L DRAQ5 (5 mmol/L stock, BioStatus DR050050) and incubated for 15 minutes at room temperature. Fixed MCF-7 and T47D cells were resuspended in PBS at a concentration of $1 \times 10^6$ cells/100 µL and stained by addition of 5 µL of 7-AAD (Thermo Fisher Scientific A1310) for 15 minutes at room temperature in the dark. Flow cytometry analysis was performed using BD FACSAria Fusion (BD Biosciences). Doublets and dead cells were excluded from the analysis. Flow cytometry data were analyzed using FlowJo 10.8.1 cytometry analysis software (FlowJo, LLC; RRID:SCR_008520).

Induction of apoptosis in response to treatment with X15695 was analyzed in MCF-7 and T47D cells using PE Annexin V Apoptosis Detection Kit with

7-AAD (BD Biosciences, 556421) according to the manufacturers protocol. In short, cells were harvested by trypsinization and single-cell suspensions ($1 \times 10^6$ cells) were prepared as described above in 100 µL PBS. Cells were stained with 5 µL PE Annexin V and 5 µL 7-AAD for 15 minutes at room temperature in the dark. Subsequently, 400 µL PBS were added to each sample and flow cytometry measurements were performed within 1 hour. Cells stained with PE Annexin V or 7-AAD alone were used for compensation. Flow cytometry analysis was performed using BD FACSAria Fusion. Flow cytometry data were analyzed using FlowJo 10.8.1 cytometry analysis software (FlowJo, LLC).

Apoptosis in LNCaP and LAPC-4 cells was measured using an automated high-throughput microscopy method as previously described under HT/C assays at KIT (25). In brief, LNCaP and LAPC4 cells ($5 \times 10^3$) were seeded in a 96-well plate format. Cells were treated with $10^{-9}$ to $10^{-6}$ mol/L X15695, DMSO or etoposide (250 µmol/L) as control for 48 hours. Cells were stained with Hoechst 33342 (0.15 µg/mL) and propidium iodide (PI; 0.25 µg/mL) for 30 minutes at 37°C. Four brightfield and fluorescence images were acquired from different positions in each well using an automated Olympus IX81 fluorescence microscope (Olympus). The Hoechst dye was detected at excitation 350 nm and emission 450 nm and PI dye was detected at 488 and 590 nm. The total number of cells (all Hoechst-stained nuclei) as well as the number of early apoptotic, late apoptotic, and necrotic cells (combination of Hoechst and PI nuclei intensity) was obtained by analyzing images with the scanR software (version 2.7.3, Olympus).

## Mouse Xenograft Experiments

All animal experiments were performed according to European and German statutory regulations and approved by the Regierungspräsidium Karlsruhe, Germany.

MCF-7 and LAPC-4 cells ($2 \times 10^6$) were suspended in 100 µL PBS: Matrigel (Corning, 354248; 1:1) and injected subcutaneously into both flanks of 6-7 weeks old female (for MCF-7 cells) and male (for LAPC-4 cells) athymic nude-Foxn1<sup>nu</sup> mice (Envigo 6901M). When tumor volumes were around 50-100 mm³, mice were randomized into four groups (7 mice per group) and treated daily by oral gavage as follows: (i) Control group (Vehicle; corn oil, 1.0% DMSO) and (ii) X15695 group, 30 mg per kg body weight) for the MCF-7 tumors or (i) Control group (Vehicle; corn oil, 1.0% DMSO), (ii) enzalutamide (Enza group, 15 mg per kg body weight), (iii) X15695 group (30 mg per kg body weight), and (iv) X15695 group (15 mg per kg body weight). Body weight and tumor volumes were measured twice a week. Tumor volume was measured with a digital vernier caliper and calculated using the formula $vol = length \times width \times height \times 0.5236$ and recorded or calculated relative to the starting volume which was nominally set at 100%. After 16 days for the MCF-7 tumors or 42 days for the LAPC-4 tumors, mice were sacrificed and the tumors removed, photographed, and weighed. Percent body weight change was calculated using the following formula: group percent weight change = [(new weight - initial weight)/initial weight] × 100. Tumors were snap-frozen and stored for Western blot analysis.

## Synthesis of Imidazopyridines (See Supplementary Data)

### Graphing and Statistical Analysis

Experiments were performed with three or more replicates. Differences between two groups were analyzed by Student t test and multiple comparisons were determined by one-way ANOVA. If there were two factors (such as dose and time) investigated, data were analyzed by two-way ANOVA followed by a
post hoc test. Data were expressed as means ± SEM, and *P* < 0.05 was considered significant. All analyses were performed using Microsoft Excel 2010 (RRID:SCR_016137) and GraphPad Prism 8.3.1 (RRID:SCR_002798) software.

## Data Availability Statement

All data relevant to the study are included in the article or Supplementary Data. The data that support the Chemistry part of this study are available in the repository Chemotion (https://www.chemotion-repository.net/). All DOIs minted for the data are linked to the specific experiments in the supporting information and a summary of all new data obtained in this study can be accessed with the collection: DOI https://dx.doi.org/10.14272/collection/SGV_2022-09-29. Crystallographic data for compounds X15695, X15696 and X19168 reported in this article have been deposited with the Cambridge Crystallographic Data Centre as supplementary information no. CCDC-2226035, 2218538, and 2218539. Copies of the data can be obtained free of charge from https://www.ccdc.cam.ac.uk/structures/. The compounds produced in this study can be requested from the Molecule Archive of KIT either upon request according to contact details given in the Supplementary Data or following the information available in Chemotion repository (https://dx.doi.org/10.14272/collection/SGV_2022-09-29).

## Results

### Growth Inhibitory Properties of Imidazopyridine Derivatives

We have previously reported that the compound A4B17 derived from a screen of 47 benzothiazoles inhibited proliferation of ER⁺ breast and AR⁺ prostate cancer cells with half maximal inhibitory concentrations (IC₅₀) in the micromolar range (19, 20). To improve on the potency of this compound, we used a scaffold hopping approach focusing on heterocycle replacement (26) to change the benzothiazole into an imidazopyridine (from core of type A to core of type B; Fig. 1A) to generate X20046 from A4B17 (Fig. 1B). This greatly improved the inhibitory properties of X20046 both in breast and prostate cancer cells (Supplementary Table S1).

We therefore synthesized a series of 27 imidazopyridines (Fig. 1C) based on the core structure of type B as given in Fig. 1A (top right), determined the X-ray structure of X15695, X15696, and X19168 (Fig. 1D; Supplementary Table S2) for rational drug design and analyzed the ability of all 27 compounds to inhibit the clonal expansion of a series of breast and prostate cancer cells. All the compounds outperformed A4B17 in the inhibition of clonal expansion of ER⁺ breast and AR⁺ prostate cancer cells and had very weak or no effect on receptor-negative cell lines (Supplementary Table S1). With only few exceptions, compounds that potently inhibited colony formation of ER⁺ cells also potently inhibited the clonal expansion of the AR⁺ prostate cancer cell lines. Six imidazopyridines, including X20046 (the imidazopyridine derivative of A4B17) were identified as particularly potent based on their IC₅₀ values in the two different cell types (Supplementary Table S1). These compounds share a striking resemblance in their core structures (Fig. 1B) and show a requirement for either a methyl group or a CF₃ group at position C-6 of the imidazopyridine core similar to other derivatives that were only active against one of the two cancer cell types analyzed. From the six identified compounds, X15695 was chosen for further study.

### Transcriptomics Analyses to Determine X15695 Action

To determine the mechanism of action of X15695, we first performed transcriptomics analyses in the ER⁺ breast cancer cell lines MCF-7 and T47D after

treating them with vehicle (DMSO), 17-β-estradiol (E₂), X15695, and a combination of E₂ and X15695. The RNA-seq datasets were analyzed using a fold change of log₂(counts per million [CPM]) ≥ 1.0 or ≤ -1.0 and a *P*<sub>adj</sub> value ≤ 0.05 to identify differentially expressed genes (DEG) in response to X15695 in the presence or absence of E₂. A total of 531 DEGs (327 DEGs downregulated and 204 DEGs upregulated) was identified in MCF-7 cells in response to X15695 in the absence of E₂ but 439 DEGs (238 DEGs downregulated and 201 DEGs upregulated) in response to X15695 in the presence of E₂ (Supplementary Fig. S1A and S1B). In the T47D cells, 487 DEGs (302 downregulated and 185 upregulated) were identified in response to X15695 in the absence of E₂ treatment while in the presence of E₂, slightly less DEGs were seen (458; 280 downregulated and 176 genes upregulated; Supplementary Fig. S1C and S1D).

To investigate the pathways associated with the X15695-mediated changes in gene expression, GSEA was performed using the Hallmarks gene sets from the Molecular Signatures Database (MSigDB, RRID:SCR_016863; ref. 27). Two of the most regulated pathways by X15695 in the presence of E₂ in MCF-7 cells were the ERα and p53 signaling pathways. In the absence of E₂, the p53 signaling pathway was also identified as the most regulated pathway (Fig. 2A and B; Supplementary Fig. S1A and S1B, right). Among other signatures, the ERα and the p53 pathways were also the most significantly regulated pathways by X15695 in the T47D cells (Supplementary Fig. S1C and S1D, right). Therefore, a heat map was generated to compare E₂ response genes in MCF-7 and T47D cells and this showed a very strong overlap in the downregulation of expression of ERα target genes in the two cell lines (Supplementary Fig. S2A). Quantitative real-time polymerase chain reaction (RT-PCR) carried out with a select number of ERα response genes in the two cells showed indeed downregulation of E₂-mediated gene expression by X15695 (Supplementary Fig. S2B and S2C). On the contrary, the p53 pathway was upregulated by X15695 in the two cell lines as shown in the heat map but more strongly in the MCF-7 cells compared with the T47D cells (Supplementary Fig. S2D). X15695-mediated upregulation of expression of p53 target genes in the absence and presence of E₂ was also confirmed in the qRT-PCR analyses, but the results in the MCF-7 cells were somewhat more prominent than in the T47D cells (Supplementary Fig. S2E and S2F).

We detected that X15695 did not only potently inhibit E₂-induced gene transcription but simultaneously increased the expression of genes negatively regulated by E₂, including genes involved in cell-cycle arrest and in the induction of apoptosis. For example, E₂-mediated downregulation of expression of CDKN1A and BBC3 in the MCF-7 cells was dose-dependently upregulated by X15695 (Fig. 2C and D). In addition, the expression of CDKN1A but not BBC3 was upregulated by X15695 in the absence of E₂ (Fig. 2E and F), making CDKN1A a gene under dual control mechanisms by E₂ and X15695. In contrast, the expression of the p53 downstream target gene BAX, was not regulated by E₂ but was transcriptionally enhanced by X15695 (Fig. 2G and H). These findings identified X15695 as a compound that targets both the ERα and p53 signaling pathways and can therefore control the actions of the p53-ER regulatory loop described in breast cancers (28).

### Mechanism of Downregulation of ERα and Upregulation of p53

We sought to investigate the possible mechanisms of X15695-mediated regulation of ERα and p53 signaling pathways in the breast cancer cells. In immunoblotting studies, X15695 dose-dependently decreased ERα level in both cell lines (Fig. 3A and B). In the MCF-7 cells, ERα staining in the absence and presence of E₂ was strongly reduced by X15695 treatment (100 nmol/L and
<figure><img src="image_3.png" /><figcaption>A</figcaption></figure>

2-phenylbenzo[d]thiazole
47 derivatives of type A

<figure><img src="image_4.png" /></figure>

2-phenylimidazo[1,2-a]pyridines
27 derivatives of type B

<figure><img src="image_5.png" /><figcaption>B</figcaption></figure>

<figure><img src="image_6.png" /><figcaption>C</figcaption></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

<figure><img src="image_10.png" /></figure>

<table><thead><tr><th>ID</th><th>R<sup>1</sup> =</th><th>R<sup>2</sup> =</th><th>R<sup>3</sup> =</th></tr></thead><tbody><tr><td>X19147</td><td>H</td><td>H</td><td>H</td></tr><tr><td>X19712</td><td>H</td><td>F</td><td>H</td></tr><tr><td>X19151</td><td>CH<sub>3</sub></td><td>H</td><td>H</td></tr><tr><td>X19718</td><td>CH<sub>3</sub></td><td>F</td><td>H</td></tr><tr><td>X19167</td><td>CH<sub>3</sub></td><td>H</td><td>F</td></tr><tr><td>X19726</td><td>Cl</td><td>H</td><td>H</td></tr><tr><td>X19727</td><td>Cl</td><td>F</td><td>H</td></tr><tr><td>X19725</td><td>Cl</td><td>H</td><td>F</td></tr></tbody></table>

<table><thead><tr><th>ID</th><th>R<sup>1</sup> =</th><th>R<sup>2</sup> =</th><th>R<sup>3</sup> =</th></tr></thead><tbody><tr><td>X15694</td><td>Cl</td><td>H</td><td>F</td></tr><tr><td>X19148</td><td>Br</td><td>H</td><td>H</td></tr><tr><td>X19719</td><td>Br</td><td>F</td><td>H</td></tr><tr><td>X19168</td><td>Br</td><td>H</td><td>F</td></tr><tr><td>X20034</td><td>CH<sub>3</sub></td><td>H</td><td>H</td></tr><tr><td>X20035</td><td>CH<sub>3</sub></td><td>F</td><td>H</td></tr><tr><td>X20036</td><td>CH<sub>3</sub></td><td>H</td><td>F</td></tr></tbody></table>

<table><thead><tr><th>ID</th><th>R<sup>1</sup> =</th><th>R<sup>2</sup> =</th><th>R<sup>3</sup> =</th></tr></thead><tbody><tr><td>X19728</td><td>Cl</td><td>H</td><td>H</td></tr><tr><td>X19729</td><td>Cl</td><td>F</td><td>H</td></tr><tr><td>X19724</td><td>Cl</td><td>H</td><td>F</td></tr></tbody></table>

<table><caption>D</caption><thead><tr><th>ID</th><th>R<sup>1</sup> =</th><th>R<sup>2</sup> =</th><th>R<sup>3</sup> =</th></tr></thead><tbody><tr><td>X20048</td><td>H</td><td>H</td><td>H</td></tr><tr><td>X15688</td><td>H</td><td>H</td><td>I</td></tr><tr><td>X15692</td><td>H</td><td>H</td><td>Br</td></tr><tr><td>X20046</td><td>H</td><td>H</td><td>F</td></tr><tr><td>X20047</td><td>H</td><td>F</td><td>H</td></tr><tr><td>X15696</td><td>Cl</td><td>H</td><td>H</td></tr><tr><td>X19720</td><td>Cl</td><td>F</td><td>H</td></tr><tr><td>X15695</td><td>Cl</td><td>H</td><td>F</td></tr><tr><td>X15689</td><td>Cl</td><td>H</td><td>F</td></tr></tbody></table>

<figure><img src="image_11.png" /></figure>

<figure><img src="image_12.png" /></figure>

<figure><img src="image_13.png" /></figure>

X15695

X15696

X19168

**FIGURE 1** Imidazopyridine structures for inhibition of prostate and breast cancer proliferation. **A**, Comparison of benzothiazole and imidazopyridine scaffolds. **B**, Chemical structures of the benzothiazole A4B17 and six imidazopyridines that potently inhibit clonal expansion of ER⁺ and AR⁺ breast and prostate cancer cells. **C**, Chemical structures showing the structure of different imidazopyridine derivatives. **D**, Crystal structures of X15695, X15696, and X19168.
<figure><img src="image_14.png" /><figcaption>**FIGURE 2** X15695 attenuates ERα-mediated target gene expression. GSEA plots of the top gene sets identified in a comparison of E₂ + X15695 versus E₂ (A) and X15695 versus vehicle (B) in MCF-7. C-H, Quantitative RT-PCR to detect the effect of X15695 on the expression of the indicated p53 target genes in MCF-7 cells in the presence and absence of E₂. Cells were treated with the indicated concentrations of X15695 in the presence and absence of 10 nmol/L E₂ for 16 hours. The data represent the mean ± SEM (n = 4; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; ns, not significant).</figcaption></figure>

1 µmol/L) in the cytoplasm and in the nucleus (Fig. 3C). A similar downregu-
lation in ERα level was observed in immunofluorescence experiments in T47D
cells (Fig. 3D), albeit in full medium without additional hormone.

To determine how X15695 downregulates ERα level, MCF-7 cells were treated
with cycloheximide to inhibit *de novo* protein synthesis and the degradation
kinetics of the steady state population of the receptor was determined. This
showed that while ERα was relatively stable (>120 minutes) in the absence of
X15695, its half-life was reduced to about 60 minutes in the presence of X15695
(Fig. 3E and F), suggesting destabilization of ERα by X15695.

In contrast to the decrease in ERα levels in both MCF-7 and T47D cells, X15695 differentially regulated the level of p53 in the two cell lines. In Western blot experiments, p53 level was significantly increased by X15695 in MCF-7 but not in T47D cells (Fig. 4A and B). Note that MCF-7 cells express a wild-type p53 while T47D cells express a mutated p53 (L194F) which may account for the difference in regulation by X15695. The upregulation of p53 expression in the MCF-7

cells did not occur at the RNA level as demonstrated in qRT-PCR experiments (Fig. 4C and D), suggesting that the regulation occurred at the protein level. As protein turnover is a dynamic process controlled by the rate of protein synthesis and degradation, inhibition of protein degradation should provide information on the contribution of the latter process to the accumulation of p53. X15695 treatment in the absence of the proteasomal inhibitor MG132 led to an accumulation of p53 in the MCF-7 cells but in the presence of MG132 (Fig. 4E), the basal level of p53 was increased and no further upregulation by X15695 was observed. Quantification of the effect of MG132 and X15695 on p53 level presented in Fig. 4F showed that X15695 functions by inhibiting proteasomal degradation of p53. In T47D cells where the proteasomal degradation pathway is reportedly nonfunctional (29, 30), mutant p53<sup>L194F</sup> accumulated in the non-treated cells and its level was unaltered by X15695 administration (Fig. 4B).

To further understand the mechanism leading to p53 accumulation, we an-
alyzed the expression level of MDM2, an E3 ubiquitin ligase that directs
<figure><img src="image_15.png" /></figure>

<figure><img src="image_16.png" /></figure>

<figure><img src="image_17.png" /></figure>

<figure><img src="image_18.png" /></figure>

<figure><img src="image_19.png" /></figure>

<figure><img src="image_20.png" /></figure>

**FIGURE 3** X15695 destabilizes ERα. Western blot analysis of ERα in extracts of MCF-7 (A) and T47D (B) cells after treatment with vehicle or the indicated concentrations of X15695 for 48 hours. Anti-β-actin antibody was used for protein loading control. The protein samples used to determine the expression level of ERα were also used for the determination of p53 levels in Fig. 4A and B. Therefore, the β-actin control levels in these experiments are identical. Representative immunofluorescent staining carried out on hormone starved MCF-7 cells (C) treated with 100 nmol/L or 1 µmol/L X15695 in the presence and absence of 10 nmol/L E₂ for 16 hours and T47D cells (D) treated with 1 µmol/L X15695 for 16 hours in full medium without hormone depletion. Staining was performed with anti-ERα antibody followed by goat anti-mouse IgG, Alexa Fluor 488 (green) and by DAPI (magenta). Fluorescence images were taken at 20×3 magnification. E, Western blot analysis of ERα in extracts of MCF-7 cells treated with vehicle or X15695 (1 µmol/L) for 24 hours followed by treatment with 100 µg/mL cycloheximide. The reaction was terminated at the indicated timepoints. Anti-β-actin antibody was used to determine equal protein loading. F, Protein signals were quantified and presented in percentages as the signal of ERα relative to the β-actin signal. The value at timepoint zero of cycloheximide treatment was set to 100%. The values are the means ± SEM, n = 3; **, P ≤ 0.01.
A MCF-7 cells

<figure><img src="image_21.png" /></figure>

B T47D cells

<figure><img src="image_22.png" /></figure>

C MCF-7 cells

<figure><img src="image_23.png" /></figure>

D T47D cells

<figure><img src="image_24.png" /></figure>

E

<figure><img src="image_25.png" /></figure>

F

<figure><img src="image_26.png" /></figure>

G MCF-7 cells

<figure><img src="image_27.png" /></figure>

H T47D cells

<figure><img src="image_28.png" /></figure>

I

<figure><img src="image_29.png" /></figure>

J T47D cells

<figure><img src="image_30.png" /></figure>

<figure><img src="image_31.png" /></figure>

<figure><img src="image_32.png" /></figure>

K

<figure><img src="image_33.png" /></figure>

L

<figure><img src="image_34.png" /></figure>

M MCF-7 cells

<figure><img src="image_35.png" /></figure>

N T47D cells

<figure><img src="image_36.png" /></figure>

**FIGURE 4** X15695 stabilizes p53. Western blot analysis of p53 in extracts of MCF-7 (A) and T47D (B) cells treated with vehicle or the indicated concentrations of X15695 for 48 hours. Anti-β-actin antibody was used for the loading control (same as it appears in Fig. 3A and B). Quantitative RT-PCR of p53 expression in MCF-7 (C) and T47D (D) cells after treatment with vehicle (DMSO) or the indicated concentrations of X15695 for 48 hours. The results are the mean ± SEM (n = 3; ns, nonsignificant). E, Western blot analysis of p53 in extracts of MCF-7 cells treated with 0.5 µmol/L MG132 in the presence and absence of 1 µmol/L X15695 for 48 hours. Anti-β-actin antibody was used for the loading control. (Continued on the following page.)
<figure><img src="image_37.png" /><figcaption>**FIGURE 5** X15695 reactivates p53. A, Western blot analysis of mortalin and p53 in immunoprecipitated extracts of MCF-7 cells treated with 1 µmol/L X15695 for 48 hours and lysed. 50 µg of cell extract was used as input control while 1,000 µg was immunoprecipitated with anti-p53 or IgG antibodies immobilized on protein A/G agarose beads. B, Western blot analysis of mortalin and BAG1 in immunoprecipitated extracts of MCF-7 cells treated with 1 µmol/L X15695 for 48 hours. MCF-7 cells were treated and processed as in A with the exception that the immunoprecipitation was carried out with a mouse anti-BAG1 antibody. C, Western blot analysis of BAG2 and BAG5 in immunoprecipitated extracts of (Continued on the following page.)</figcaption></figure>
(Continued) T47D cells treated with 1 µmol/L X15695 for 48 hours. A total of 70 µg of cell extracts was used as input control while 1,000 µg was immunoprecipitated with anti-p53 or IgG antibodies immobilized on protein A/G agarose beads. D, Western blot analysis of p53 protein after transfection of MCF-7 and T47D cells with control and p53 siRNA and treatment with vehicle or X15695 (1 µmol/L) for 24 hours. β-actin was used for the loading control. E, Cell viability determination using MTT assay in control and p53 siRNA transfected cells treated with vehicle or X15695 (1 µmol/L) for 72 hours (n ≥ 3; ***, * P ≤ 0.001; * P ≤ 0.05). Cell-cycle analysis of MCF-7 (F) and T47D (G) cells treated with vehicle or 1 µmol/L X15695 for 48 hours. A total of 1 × 10⁶ cells were stained with 7-AAD and used for flow cytometry measurement. Data were analyzed by FlowJo software. Apoptosis assessment of MCF-7 (H) and T47D (I) cells treated with 1 µmol/L X15695 for 48 hours. The cells were double stained with 7-AAD and Annexin V. Cells stained with 7-AAD or Annexin V alone were used for compensation of double staining. A total of 1 × 10⁶ cells were used for the flow cytometry measurement. The quantified results are the mean ± SEM (n = 3; * P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.0001; ns is non-significant).

tamoxifen was again inactive while X15695 and fulvestrant were both active, with fulvestrant being slightly more efficacious than X15695 (Fig. 6D and E).

Although oral administration is a more preferred route of drug administra-
tion, the low aqueous solubility of fulvestrant requires it to be administered
intramuscularly (6–8). X15695 differs from fulvestrant in that it was found to
significantly decrease tumor volume and weight within 2 weeks after oral appli-
cation to a mouse xenograft tumor model (30 mg/kg body weight daily; Fig. 6F
and H). In that study, X15695 was well tolerated and did not cause any weight
loss or other signs of host toxicity (Fig. 6I). Western blot analysis of lysates from
the tumors after the treatment period showed a significant decrease in ERα level
and an increase in p53 expression, in line with the results in the cell culture
experiments (Fig. 6J and L).

**Regulation of AR<sup>+</sup> Prostate Cancer Cells by Imidazopyridine Derivatives**

As the imidazopyridines analyzed for the inhibition of clonal expansion of ER+ breast cancer cells also inhibited proliferation of AR+ prostate cancer cells (Supplementary Table S1), it is possibility that these compounds function through a common antitumor pathway. We therefore first investigated whether BAG1 played a role in the action of X15695 in the prostate tumor cells using BAG1 knockdown LNCaP prostate cancer cells. Two BAG1 shRNA clones that showed a clear reduction in BAG1 level compared with the control clone (Fig. 7A) showed a decrease in the IC50 concentration for inhibition of clonal expansion (Fig. 7B), suggesting a contribution of BAG1 to proliferation of these cells. Unlike the breast cancer studies, treatment with X15695 did not strongly downregulate AR level in LNCaP prostate cancer cells nor in the castration-resistant prostate cancer (CRPC) cell line 22Rv.1 (Fig. 7C). Nonetheless, transcriptomics experiments carried out with LNCaP cells showed an X15695-mediated attenuation of androgen response. Specifically, GSEA showed that in the presence of DHT, androgen signaling pathway, G2-M cell-cycle arrest, and E2F pathways were attenuated by X15695, while only the latter two were attenuated in the absence of DHT (Fig. 7D and F). RT-PCR studies confirmed that X15695 downregulated a select number of classical AR target genes (KLK3, FKBP5, F5) and androgen-induced ROS genes (MICAL1, SAT1, DUOX1) previously identified as BAG1 sensitive targets (20) and also identified in the present RNA-seq study (Fig. 7D and G). X15695 was found to be a better inhibitor of AR-target gene expression compared with the five other imidazopyridines identified previously (compare Fig. 7G with Supplementary Fig. S4). However, in studies to determine the ability of the imidazopyridines to stabilize p53 expression in three different prostate cancer cell lines (22Rv.1 LNCaP, LAPC-4), none of the compounds strongly stabilized p53 (Supplementary Fig. S5A). However, we focused on X15695 for further analysis in the prostate cancer cells for better comparison with the studies in the breast cancer cells.

We next investigated whether X15695 caused nuclear translocation of p53 as was observed in the MCF-7 cells. Note that the prostate cancer cells have different p53 status: LNCaP cells express wild-type p53; 22Rv.1 cells express wtp53/mtp53Q331R and LAPC-4 cells express mtp53R175H. In immunofluorescence experiments, X15695 promoted a cytoplasmic/nuclear translocation of p53 in cells that express wild-type p53 (LNCaP and 22Rv.1) but not in the LAPC-4 cells that express only mutant p53. In the latter cell line, p53 was already nuclear and X15695 did not alter its cellular localization (Supplementary Fig. S5B). To determine whether p53 plays a role in the inhibitory action of X15695 in the prostate cancer cells, an attenuation of the X15695-mediated decrease in viability of the three prostate cancer cells was determined after p53 knockdown by siRNA transfection (Fig. 7H). Decreased viability observed after X15695 treatment was significantly compromised in all three cell lines transfected with p53 siRNA (Fig. 7I), indicating a contribution of p53 to the growth inhibitory action of X15695 in these cells. Flow cytometric analysis was also determined to assess the downstream effects of p53 on cell-cycle arrest or the induction of apoptosis in the prostate cancer cells following treatment with X15695. We found out that X15695 induced G₁-S-phase arrest in the LNCaP cells and a G₂-M arrest in the LAPC-4 cells (Fig. 8A and B). No apoptotic effect of X15695 was identified in either prostate cancer cell type (Supplementary Fig. S6), indicating an effect mediated primarily by the cell-cycle arrest.

X15695 Inhibits Prostate Tumor Growth in a Mouse Xenograft Model

To determine whether the cell-cycle block and the antiandrogen action of X15695 are sufficient to inhibit prostate tumor growth, we carried out mouse tumor xenograft experiments using LAPC-4 cells. We compared the action of X15695 (10 and 30 mg/kg) with the classical antiandrogen enzalutamide (10 mg/kg) over 42 days. X15695 effectively inhibited tumor growth over vehicle upon oral administration (30 mg/kg/day), albeit less effectively compared with enzalutamide (10 mg/kg/day; Fig. 8C and D), identifying X15695 as a weaker AR antagonist in this tumor model. As with the MCF-7 cell xenograft experiment, X15695 was well tolerated in the study with no signs of toxicity or weight loss (Fig. 8E).

X15695 is Selective for ER+ Breast Cancer

The negative action of X15695 on proliferation of AR+ prostate and ER+ breast cancer, posed the question whether the proliferation of other tumor cells could be inhibited by this compound. X15695’s effect on the clonal expansion of cervical, lung, and osteosarcoma (HeLa, A549, and U2OS) cells was compared with its effect on MCF-7 cells. While X15695 dose-dependently inhibited the clonal expansion of MCF-7 cells, it did not have any significant effect on the other tumors cell lines (Fig. 8F).

Collectively, these results demonstrate that X15695 inhibits proliferation of
breast cancer cells and prostate cancer cells but its strong effect on the
<figure><img src="image_38.png" /><figcaption>**FIGURE 6** X15695 and fulvestrant downregulate ERα level and proliferation of breast cancer cell proliferation A, Western blot analysis of ERα in extracts of MCF-7 cells treated for the indicated timepoints with 1 µmol/L of fulvestrant or X15695 or DMSO (vehicle). β-actin was used for the loading control. The protein signals were quantified and presented in percentages as the signal of ERα relative to the β-actin signal (right). The value at zero time of treatment was set to 100%. The values are the mean ± SEM (n = 3; \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001). B, Western blot analysis of ERα in extracts of MCF-7 cells treated with the indicated concentration of fulvestrant or X15695 for 8 hours. β-actin was (Continued on the following page.)</figcaption></figure>
(Continued) used for the loading control. The protein signals were quantified and presented in percentages relative to the vehicle-treated sample (right). The values are the mean ± SEM (n = 3; ****, P ≤ 0.0001). C, Measurement of cell viability by MTT assay of tamoxifen resistant cells (TRMCF-7) treated with the indicated concentrations of X15695, fulvestrant, and tamoxifen for 48 hours. Five replicates were used for each experiment, and the experiment was repeated three times (**, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; ns, nonsignificant). D, Representative image of a clonogenic assay showing the effect of the indicated concentrations of X15695, fulvestrant, and tamoxifen on clonal expansion of tamoxifen-resistant MCF-7 cells. E, Quantification of colonies in the clonogenic assay described in D. F, Representative images of some of the tumors obtained in a mouse MCF-7 tumor xenograft after treatment with vehicle and X15695. G, Tumor volumes of established subcutaneous MCF-7 xenografts treated daily via oral gavage with vehicle or X15695 (30 mg/kg body weight). The values are the mean ± SEM (*, P = 0.05; n = 14). H, Tumor weights at the end of treatment were recorded and presented in the bar chart. The values are the means ± SEM (*, P = 0.05; n = 14). I, Mouse body weights measured twice weekly for all animals over 16 days. Presented are the mouse body weight changes, in percentages, for each group. J, Western blots analysis of ERα and p53 from the extracts of select tumors at the end of treatment. Anti-vinculin antibody was used to determine the level of protein loaded. Quantification of ERα (K) and p53 (L) protein levels in select tumors relative to the vinculin loading control. The results are the mean ± SEM. *, P ≤ 0.05; ***, P ≤ 0.001; n = 12.

degradation of ERα combined with the reactivation of p53 makes it a superior inhibitor of ER⁺ breast cancer cells than AR⁺ prostate cancer cells. These effects combined with its lack of action in inhibiting proliferation of other cancer cells warrants X15695 to be classified as an oral SERD.

Discussion

In this study, a compound with an imidazopyridine scaffold X15695 was shown to strongly downregulate ERα activity and to a lower extent AR action and to reactivate wild-type and mutant p53. As a consequence, X15695 inhibited proliferation of ER⁺ breast cancer and AR⁺ prostate cancer cells in vitro and in vivo in xenograft models. However, in the in vivo studies, X15695 was more efficacious in inhibiting breast cancer than prostate cancer cell proliferation. X15695 action was selective as no inhibition of proliferation was detected in steroid receptor negative breast or prostate cancer cells or other tumor cells analyzed that lack expression of gonadal steroid receptors.

Imidazopyridine-based compounds to which X15695 belongs have gained significant attention in medicinal chemistry due to their frequent occurrence in a large number of marketed drug formulations and drug candidates. These compounds have a wide variety of biological and pharmacologic activities such as antimycobacterial, antidiabetic, antiviral, and anticancer activities (41). For anticancer action, a library of amide derivatives of imidazopyridine has been shown to be highly potent in inhibiting the proliferation of breast (MCF-7, MDA MB-231), lung (A549), and prostate (DU145) cancer cell lines (42). Recently, imidazopyridine compounds that inhibit PI3K/Akt and the proliferation of AR⁺ and AR⁻ CRPC cells have been described (43, 44). However, the high concentrations of these compounds (up to 10 µmol/L) required for the inhibition of CRPC proliferation question their on-target mode of action.

Several *in vitro* experimental observations have shown that the anticancer effect of the imidazopyridine compounds results mainly from their inhibitory effects on six main molecular targets: PI3K/Akt, centromere-associated protein E (CENP-E), insulin-like growth factor-1 receptor (IGF-1R), cyclin-dependent kinases (CDK), tubulin polymerization, and hepatocyte growth factor receptor (45). So far, steroid receptors and p53 have not been identified as molecular targets for imidazopyridines.

We have shown that X15695 inhibits proliferation of tumor cells that express ERα and AR as well as the transactivation function of these two receptors but its effect is more profound on ERα compared with the AR-expressing

tumor cells. Although the primary target(s) of action of X15695 have not been identified in this work, there is a link to the BAG domain of the BAG family of proteins through docking experiments performed with the related A4B17 molecule (19). The BAG family is a multifunctional protein family that performs diverse functions ranging from the control of cell proliferation, apoptosis to tumorigenesis. This family is made up of six proteins [BAG1, BAG2, BAG3 (CAIR-1/Bis), BAG4 (SODD), BAG5, and BAG6], each with at least one conserved BAG domain made up of three anti-parallel alpha helical bundles of 30-40 amino acids (12). They use this BAG domain to interact with the ATPase binding domain of the molecular chaperone HSP70/HSC70 to function as nucleotide exchange factors (46). BAG domain/HSP70/HSC70 complexes have also been reported to interact with several client proteins to mediate the biological action of these proteins and small molecules that disrupt these interactions have been suggested to be potential therapeutic drugs (47).

We have previously reported that A4B17 that is structurally related to X15695 disrupts interaction of BAG1L with the N-terminus of the AR, that is otherwise required for the activity of this receptor (19). A possibility exists that X15695 also disrupts interaction of BAG1 with ERα (16) to account for its inhibitory action on E₂ target gene expression in the ER⁺ breast cancer cells. We have also shown that X15695 regulates p53 action by disrupting the interactions of mortalin with wild-type p53 and also of BAG1 with mortalin. Although the disruption of mortalin-p53 interaction by X15695 could be a result of its action on mortalin-BAG1 interaction, we cannot rule out an independent direct action of X15695 on mortalin-p53 interaction. We showed that treatment with X15695 disrupts the cytoplasmic retention of p53 by mortalin leading to nuclear translocation of p53 and the activation of the cell-cycle regulator p21 and the apoptotic action of p53. Reactivation of p53 has become a challenge in drug discovery programs for anticancer therapies. Several small-molecule inhibitors are reported to disrupt mortalin-p53 interaction to reactivate p53. Among them is Mortaparib<sup>plus</sup> that inhibits the proliferation of MCF-7 cells. However, Mortaparib<sup>plus</sup> reactivates only wild-type p53 and not mutant p53 in T47D cells (35, 48). Other compounds such as PRIMA-1 and its methyl analog Eprenetapopt (APR-246) are reported to reactivate mutant p53 (49, 50). APR-246, for example, is a first-in-class small molecule that restored wild-type p53 functions in TP53-mutant cells and is currently in phase II clinical trials (51). Unlike Mortaparib<sup>plus</sup> and APR-246, we have shown in this study that X15695 reactivates both wild-type and mutant p53. With mutant p53, we have shown that it disrupts its interaction with BAG2 and the GOF action of mutant p53. These findings together speak in favor of X15695 being a regulator of
<figure><img src="image_39.png" /><figcaption>**FIGURE 7** X15695-mediated regulation of AR action in prostate cancer cells. A, Western blot analysis of BAG1 in LNCaP cells transduced with BAG-1 shRNA and control shRNA. Antibodies to vinculin, AR, tubulin, and GAPDH were used as controls. B, Quantification of the effect of X15695 on clonal expansion of control and BAG1 shRNA knockdown LNCaP cells. Each point represents the mean ± SEM. *n* = 3. C, Western blot analysis of AR and BAG1 in extracts of LNCaP and 22Rv.1 cells treated with the indicated concentrations of X15695 for 24 hours. β-actin was used as a loading control. D–F, GSEA plots of the topmost signaling pathways and heat maps of log₂ fold-change in gene expression in the comparison of DHT + X15695 versus DHT and X15695 versus vehicle in LNCaP cells. G, Quantitative RT-PCR was carried to detect the effect of X15695 on DHT-mediated expression of the indicated target genes in LNCaP cells. Cells were treated with vehicle or 10 nmol/L DHT and X15695 (5 µmol/L) for 16 hours. The results are the means ± SEM (n = 4; \*, P ≤ 0.05; \***, P ≤ 0.001; \****, P ≤ 0.0001; ns, not significant). H, 22Rv.1, LAPC-4, and LNCaP cells were transfected with control and p53 siRNA for 16 hours and treated with vehicle or X15695 (5 µmol/L) for 24 hours. Western blot analysis was performed with anti-p53 and anti-β-actin antibodies. I, MTT cell viability assay carried out with 22Rv.1, LAPC-4, and LNCaP cells previously transfected with control and p53 siRNA and treated with vehicle and X15695 for 72 hours. The results are the mean ± SEM (n = 3; \*, P ≤ 0.05).</figcaption></figure>
<figure><img src="image_40.png" /></figure>

<figure><img src="image_41.png" /></figure>

<figure><img src="image_42.png" /></figure>

<figure><img src="image_43.png" /><figcaption>**FIGURE 8** X15695 induces cell-cycle arrest and inhibits proliferation of AR⁺ and ER⁺ prostate and breast cancer cells. Cell-cycle profile measured by flow cytometry of LNCaP (A) and LAPC-4 cells (B) treated with vehicle or 1 µmol/L X15695 for 48 hours. Cells for flow cytometry were stained with DRAQ5. The quantified results are the mean ± SEM (n = 3; *, P ≤ 0.05; **, P ≤ 0.01). C, Representative examples of LAPC-4 xenograft mouse tumors after daily treatment with vehicle, X15695 (10 and 30 mg/kg), and enzalutamide (10 mg/kg) for 43 days. D, Tumor weights at the end of treatment were recorded and presented as a bar chart. The values are the means ± SEM expressed (**, P ≤ 0.01; ****, P ≤ 0.0001; n = 14; ns, not significant). E, Mouse body weights were measured twice weekly over the 43 days. Presented are the mouse body weight changes, in percentages, for each group. F, Quantification of the effect of the indicated concentrations of X15695 on clonal expansion of the indicated tumor cells (n = 3).</figcaption></figure>
protein-protein interactions involving the HSP70/HSC70 chaperone/co-chaperone complex.

Two main types of mutant “hotspot” sites exist in p53: contact mutants (R273H, R248Q, and R248W) and conformational mutants (R175H, G245S, R249S, and R282H), both affecting the DNA-binding activity and the transcriptional downstream targets of p53 (52). Contact mutants generally produce structural changes in the p53 protein that directly affect DNA binding, while conformational mutants generate structural changes related to protein folding, but both types of mutants have GOF activities (53). So far BAG2 and BAG5 are reported to bind both types of mutant p53 (39, 40) for their tumorigenic activities. From our results in this work on X15695-mediated disruption of BAG2-mutp53 interaction, the proliferation of a large number of tumor cells with mutant p53 status would be expected to be inhibited by X15695. This was evidently not the case as X15695 did not significantly alter the proliferation of the ER⁻ breast cancer cell line MDA-MB231 that expresses mutp53 (R280K), or the AR⁻ prostate tumor cell line DU145 that expresses mutp53 (P223L/V274F). These findings suggest that other regulatory factors in addition to p53 are required for X15695 to exert its maximum inhibitory action. These other regulatory factors could be the steroid receptors.

One of the important findings of this work is that X15695 downregulates ERα levels which puts it in the class of ER degraders to which the clinically approved antiestrogen fulvestrant belongs. However, unlike fulvestrant that requires intramuscular injection (9), X15695, when given orally, reduces ERα levels in two weeks in a xenograft tumor model. A further advantage of X15695 is that it induces cell-cycle arrest and apoptosis to enhance its antitumor action in breast cancer cells without the need for the combination drug therapy suggested for fulvestrant. To improve the anticancer action of fulvestrant, it is recommended to have it administered with other targeted therapies such as CDK4/CDK6 inhibitors (e.g., Palbociclib) that promote cell-cycle block at the G₁-S phase (54). X15695 decreases ERα levels and induces cell cycle arrest and apoptosis on its own. The multi-targeting of factors by one compound characterizes the uniqueness of action of X15695 in this study. The actions of X15695 described here identify X15695 as a selective oral ERα degrader that warrants further development as an ER⁺ breast cancer therapeutic.

## Authors' Disclosures

M. Pan reports personal fees from China Scholarship Council during the conduct of the study; in addition, M. Pan has a patent to EP 2315696.0 pending. V. Solozobova reports a patent to Patent issued. N.C. Kuznik reports a patent to Anti-cancer Action of BAG1-Selective Imidazopyridine Compounds in Steroid Hormone Receptor-Positive Breast and Prostate Cancer licensed and with royalties paid. S. Gräßle reports a patent to Anti-cancer Action of BAG1-Selective Imidazopyridine compounds in steroid hormone receptor-positive breast and prostate cancer pending. A. Sharp reports other from Sanofi, Roche-Genentech, Astellas Pharma, Merck Sharp & Dohme, DE Shaw Research, and CHARM therapeutics outside the submitted work; and A. Sharp is an employee of the Institute of Cancer Research, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). A. Sharp has been the CI/PI of industry-sponsored clinical trials. L. Cato reports grants from Claudia Adams Barr Award and Prostate Cancer Foundation during the conduct of the study; and L.

Cato is a current employee of Sanofi. R.M. Jeselsohn reports grants from Lilly, personal fees from GE Healthcare, and other from Carrick Therapeutics outside the submitted work. V. Orian-Rousseau is a shareholder in Amcure, a start-up company that develop CD44v6 peptides against cancer. However, the CD44 peptides were not used in this study and the work submitted has no relation to the activities of amcure. S. Bräse reports a patent to Patent pending. A.C.B. Cato reports grants from Sander Stiftung during the conduct of the study; in addition, A. Cato has a patent to EP 2315696.0 pending. No disclosures were reported by the other authors.

## Authors' Contributions

**M. Pan:** Conceptualization, data curation, software, formal analysis, investigation, visualization, methodology, writing-review and editing. **V. Solozobova:** Data curation, formal analysis, validation, investigation, writing-review and editing. **N.C. Kuznik:** Data curation, formal analysis, validation, investigation, methodology, writing-review and editing. **N. Jung:** Conceptualization, resources, data curation, formal analysis, supervision, investigation, methodology, writing-original draft, writing-review and editing. **S. Gräßle:** Resources, data curation, formal analysis, validation, investigation, methodology, writing-original draft, writing-review and editing. **V. Gourain:** Data curation, software, formal analysis, validation, investigation, writing-review and editing. **Y.M. Heneka:** Resources, data curation, formal analysis, validation, investigation, writing-review and editing. **C.A. Cramer von Clausbruch:** Conceptualization, resources, data curation, formal analysis, validation, investigation, methodology. **O. Fuhr:** Resources, data curation, formal analysis, validation, investigation, methodology. **R.S.N. Munuganti:** Conceptualization, resources, methodology. **D. Maddalo:** Conceptualization. **C. Blattner:** Conceptualization, resources, writing-review and editing. **A. Neeb:** Resources, data curation, formal analysis, writing-review and editing. **A. Sharp:** Resources, data curation, writing-review and editing. **L. Cato:** Conceptualization. **C. Weiss:** Conceptualization, supervision, validation, methodology, writing-review and editing. **R.M. Jeselsohn:** Conceptualization, resources. **V. Orian-Rousseau:** Resources, supervision, methodology. **S. Bräse:** Conceptualization, resources, formal analysis, supervision, methodology. **A.C.B. Cato:** Conceptualization, formal analysis, supervision, funding acquisition, validation, writing-original draft, project administration, writing-review and editing.

## Acknowledgments

We thank Jutta Stober, Selma Huber, and Joanna Diak for their excellent technical assistance. This work was supported by a grant from the Wilhelm Sander-Stiftung (no. 2018.142.2 to A.C.B. Cato). M. Pan received funding from the China Scholarship Council (CSC), grant no. 201807090113. A. Sharp has received support from Prostate Cancer UK, Medical Research Council, and Prostate Cancer Foundation.

## Note

Supplementary data for this article are available at Cancer Research Communications Online (https://aacrjournals.org/cancerrescommun/).

Received March 08, 2023; revised May 09, 2023; accepted June 29, 2023; published first July 27, 2023.
References

1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022;66: 15-23.

2. Keen JC, Davidson NE. The biology of breast carcinoma. Cancer 2003;97: 825-33.

3. Dhingra K. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer Invest 2001;19: 649-59.

4. Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf 2015;14: 921-34.

5. Fanning SW, Greene GL. Next-generation ERα inhibitors for endocrine-resistant ER+ breast cancer. Endocrinology 2019;160: 759-69.

6. Robertson JF. Fulvestrant (Faslodex) – how to make a good drug better. Oncologist 2007;12: 774-84.

7. Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004;90: S7-10.

8. van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van Faassen M, Kema IP, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov 2015;5: 72-81.

9. Downton T, Zhou F, Segara D, Jeselsohn R, Lim E. Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status. Drug Des Devel Ther 2022;16: 2933-48.

10. Hernando C, Ortega-Morillo B, Tapia M, Moragón S, Martínez MT, Eroles P, et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: Present and future from a clinical perspective. Int J Mol Sci 2021;22: 7812.

11. Wang Y, Tang SC. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer Metastasis Rev 2022;41: 975-90.

12. Takayama S, Reed JC. Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 2001;3: E237-41.

13. Lee II, Kuznik NC, Rottenberg J, Brown M, Cato AC. Bag-1L: a promising therapeutic target for androgen receptor-dependent prostate cancer. J Mol Endocrinol 2019;62: R289-99.

14. Mariotto E, Viola G, Zanon C, Aveic S. A BAG's life: every connection matters in cancer. Pharmacol Ther 2020;209: 107498.

15. Da Costa CR, Villadiego J, Sancho R, Fontana X, Packham G, Nateri AS, et al. Bag1-L is a phosphorylation-dependent coactivator of c-Jun during neuronal apoptosis. Mol Cell Biol 2010;30: 3842-52.

16. Cutress RI, Townsend PA, Sharp A, Maison A, Wood L, Lee R, et al. The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene 2003;22: 4973-82.

17. Shatkina L, Mink S, Rogatsch H, Klocker H, Langer G, Nestl A, et al. The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol 2003;23: 7189-97.

18. Gennaro VJ, Wedegaertner H, McMahon SB. Interaction between the BAG1S isoform and HSP70 mediates the stability of anti-apoptotic proteins and the survival of osteosarcoma cells expressing oncogenic MYC. BMC Cancer 2019;19: 258.

19. Kuznik NC, Solozobova V, Jung N, Gräßle S, Lei Q, Lewandowski EM, et al. Development of a benzothiazole scaffold-based androgen receptor N-terminal inhibitor for treating androgen-responsive prostate cancer. ACS Chem Biol 2021;16: 2103-8.

20. Kuznik NC, Solozobova V, Lee II, Jung N, Yang L, Nienhaus K, et al. A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway. iScience 2022;25: 104175.

21. Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, et al. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat 2014;144: 263-72.

22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-50.

23. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34: 267-73.

24. Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 2014;9: e92444.

25. Hansjosten I, Rapp J, Reiner L, Vatter R, Fritsch-Decker S, Peravali R, et al. Microscopy-based high-throughput assays enable multi-parametric analysis to assess adverse effects of nanomaterials in various cell lines. Arch Toxicol 2018;92: 633-49.

26. Sun H, Tawa G, Wallqvist A. Classification of scaffold-hopping approaches. Drug Discov Today 2012;17: 310-24.

27. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 2015;1: 417-25.

28. Berger C, Qian Y, Chen X. The p53-estrogen receptor loop in cancer. Curr Mol Med 2013;13: 1229-40.

29. Yamamoto S, Iwakuma T. Regulators of oncogenic mutant TP53 gain of function. Cancers 2018;11: 4.

30. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer 2009;101: 1606-12.

31. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387: 296-9.

32. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387: 299-303.

33. Shi T, van Soest DMK, Polderman PE, Burgering BMT, Dansen TB. DNA damage and oxidant stress activate p53 through differential upstream signaling pathways. Free Radic Biol Med 2021;172: 298-311.

34. Kilbas PO, Can ND, Kizilboga T, Ezberci F, Doganay HL, Arisan ED, et al. CRISPR/Cas9-mediated Bag-1 knockout increased mesenchymal characteristics of MCF-7 cells via Akt hyperactivation-mediated actin cytoskeleton remodeling. PLoS One 2022;17: e0261062.

35. Elwakele A, Sari AN, Dhanjal JK, Meidinna HN, Sundar D, Kaul SC, et al. Mutant p53L194F harboring luminal-A breast cancer cells are refractory to apoptosis and cell cycle arrest in response to mortaparibplus, a multimodal small molecule inhibitor. Cancers 2021;13: 3043.

36. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998;273: 29586-91.

37. Gestl EE, Böttger SA. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochem Biophys Res Commun 2012;423: 411-6.

38. Maddalo D. Growth inhibitory action of distinct sequences derived from the co-chaperone Bag-1L. Karlsruhe Institute of Technology, PhD thesis, Karlsruhe; 2009.

39. Yue X, Zhao Y, Liu J, Zhang C, Yu H, Wang J, et al. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function. Elife 2015;4: e08401.

40. Yue X, Zhao Y, Huang G, Li J, Zhu J, Feng Z, et al. A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis. Cell Discov 2016;2: 16039.

41. Khatun S, Singh A, Bader GN, Sofi FA. Imidazopyridine, a promising scaffold with potential medicinal applications and structural activity relationship (SAR): recent advances. J Biomol Struct Dyn 2022;40: 14279-302.

42. Rani CS, Reddy AG, Susithra E, Mak K-K, Pichika MR, Reddymasu S, et al. Synthesis and anticancer evaluation of amide derivatives of imidazo-pyridines. Med Chem Res 2021;30: 74-83.
43. Muniyan S, Chou YW, Ingersoll MA, Devine A, Morris M, Odero-Marah VA, et al. Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells. Cancer Lett 2014;353: 59-67.

44. Ingersoll MA, Lyons AS, Muniyan S, D'Cunha N, Robinson T, Hoelting K, et al. Novel imidazopyridine derivatives possess anti-tumor effect on human castration-resistant prostate cancer cells. PLoS One 2015;10: e0131811.

45. Altaher AMH, Adris MA, Aliwaini SH. Imidazo[1,2-a]pyridine based compounds: the hopeful anti-cancer therapy. Syst Rev Pharm 2021;12: 79-86.

46. Sondermann H, Scheufler C, Schneider C, Hohfeld J, Hartl FU, Moarefi I. Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors. Science 2001;291: 1553-7.

47. Assimon VA, Gillies AT, Rauch JN, Gestwicki JE. Hsp70 protein complexes as drug targets. Curr Pharm Des 2013;19: 404-17.

48. Elwakeel A. Abrogating the interaction between p53 and mortalin (Grp75/HSPA9/mtHsp70) for cancer therapy: the story so far. Front Cell Dev Biol 2022;10: 879632.

49. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8: 282-8.

50. Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol 2016;6: 21.

51. Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol 2021;39: 1584-94.

52. Alvarado-Ortiz E, de la Cruz-López KG, Becerril-Rico J, Sarabia-Sánchez MA, Ortiz-Sánchez E, García-Carrancá A. Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches. Front Cell Dev Biol 2021;8: 607670.

53. Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ 2018;25: 161-8.

54. Nathan MR, Schmid P. A review of fulvestrant in breast cancer. Oncol Ther 2017;5: 17-29.